Cargando…

Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus

Influenza virus M2 protein has a highly conserved ectodomain (M2e) as a cross-protective antigenic target. We investigated the antigenic and immunogenic properties of tandem repeat M2e (5xM2e) proteins and virus-like particles (5xM2e VLP) to better understand how VLP and protein platform vaccines in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ki-Hye, Kwon, Young-Man, Lee, Young-Tae, Kim, Min-Chul, Hwang, Hye Suk, Ko, Eun-Ju, Lee, Youri, Choi, Hyo-Jick, Kang, Sang-Moo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313937/
https://www.ncbi.nlm.nih.gov/pubmed/30241300
http://dx.doi.org/10.3390/vaccines6040066
_version_ 1783384046436352000
author Kim, Ki-Hye
Kwon, Young-Man
Lee, Young-Tae
Kim, Min-Chul
Hwang, Hye Suk
Ko, Eun-Ju
Lee, Youri
Choi, Hyo-Jick
Kang, Sang-Moo
author_facet Kim, Ki-Hye
Kwon, Young-Man
Lee, Young-Tae
Kim, Min-Chul
Hwang, Hye Suk
Ko, Eun-Ju
Lee, Youri
Choi, Hyo-Jick
Kang, Sang-Moo
author_sort Kim, Ki-Hye
collection PubMed
description Influenza virus M2 protein has a highly conserved ectodomain (M2e) as a cross-protective antigenic target. We investigated the antigenic and immunogenic properties of tandem repeat M2e (5xM2e) proteins and virus-like particles (5xM2e VLP) to better understand how VLP and protein platform vaccines induce innate and protective adaptive immune responses. Despite the high antigenic properties of 5xM2e proteins, the 5xM2e VLP was superior to 5xM2e proteins in inducing IgG2a isotype antibodies, T cell responses, plasma cells and germinal center B cells as well as in conferring cross protection. Mice primed with 5xM2e VLP were found to be highly responsive to 5xM2e protein boost, overcoming the low immunogenicity and protective efficacy of 5xM2e proteins. Immunogenic differences between VLPs and proteins in priming immune responses might be due to an intrinsic ability of 5xM2e VLP to stimulate dendritic cells secreting T helper type 1 (Th1) cytokines. We also found that 5xM2e VLP was effective in inducing inflammatory cytokines and chemokines, and in recruiting macrophages, monocytes, neutrophils, and CD11b(+) dendritic cells at the injection site. Therefore, this study provides evidence that 5xM2e VLP is an effective vaccine platform, inducing cross-protection by stimulating innate and adaptive immune responses.
format Online
Article
Text
id pubmed-6313937
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63139372019-01-07 Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus Kim, Ki-Hye Kwon, Young-Man Lee, Young-Tae Kim, Min-Chul Hwang, Hye Suk Ko, Eun-Ju Lee, Youri Choi, Hyo-Jick Kang, Sang-Moo Vaccines (Basel) Article Influenza virus M2 protein has a highly conserved ectodomain (M2e) as a cross-protective antigenic target. We investigated the antigenic and immunogenic properties of tandem repeat M2e (5xM2e) proteins and virus-like particles (5xM2e VLP) to better understand how VLP and protein platform vaccines induce innate and protective adaptive immune responses. Despite the high antigenic properties of 5xM2e proteins, the 5xM2e VLP was superior to 5xM2e proteins in inducing IgG2a isotype antibodies, T cell responses, plasma cells and germinal center B cells as well as in conferring cross protection. Mice primed with 5xM2e VLP were found to be highly responsive to 5xM2e protein boost, overcoming the low immunogenicity and protective efficacy of 5xM2e proteins. Immunogenic differences between VLPs and proteins in priming immune responses might be due to an intrinsic ability of 5xM2e VLP to stimulate dendritic cells secreting T helper type 1 (Th1) cytokines. We also found that 5xM2e VLP was effective in inducing inflammatory cytokines and chemokines, and in recruiting macrophages, monocytes, neutrophils, and CD11b(+) dendritic cells at the injection site. Therefore, this study provides evidence that 5xM2e VLP is an effective vaccine platform, inducing cross-protection by stimulating innate and adaptive immune responses. MDPI 2018-09-20 /pmc/articles/PMC6313937/ /pubmed/30241300 http://dx.doi.org/10.3390/vaccines6040066 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Ki-Hye
Kwon, Young-Man
Lee, Young-Tae
Kim, Min-Chul
Hwang, Hye Suk
Ko, Eun-Ju
Lee, Youri
Choi, Hyo-Jick
Kang, Sang-Moo
Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus
title Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus
title_full Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus
title_fullStr Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus
title_full_unstemmed Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus
title_short Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus
title_sort virus-like particles are a superior platform for presenting m2e epitopes to prime humoral and cellular immunity against influenza virus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313937/
https://www.ncbi.nlm.nih.gov/pubmed/30241300
http://dx.doi.org/10.3390/vaccines6040066
work_keys_str_mv AT kimkihye viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus
AT kwonyoungman viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus
AT leeyoungtae viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus
AT kimminchul viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus
AT hwanghyesuk viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus
AT koeunju viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus
AT leeyouri viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus
AT choihyojick viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus
AT kangsangmoo viruslikeparticlesareasuperiorplatformforpresentingm2eepitopestoprimehumoralandcellularimmunityagainstinfluenzavirus